AbbVie Inc. (NYSE:ABBV) was trading at around $263 on October 5, up 14.18% over twelve months. Its payout ratio is 190.40%. The company distributes nearly twice what it reports as profit.
A dividend that large is either about to be cut or is being paid out of something the earnings line does not show.
READ ALSO: Here is Why Tripadvisor (TRIP) is a Bad Investment at Today’s Price
The Cash Is There, and the Earnings Are Not:
AbbVie reported net income of $6.27 billion and generated $16.87 billion of free cash flow. Dividends are paid from the second number, so a ratio measured against the first is describing depressed earnings rather than a company living beyond its means.
The margins show what depresses them. Operating margin is 40.04%. Net margin is 9.80%. Thirty points vanish between those lines, and where they vanish matters. Costs that high sitting below the operating line are not the business failing to earn. They are the amortization of a drug portfolio AbbVie bought rather than discovered, plus interest on the debt that bought it.
Neither leaves the building as cash in the year it is booked, which is why operating cash flow was $19.51 billion against $6.27 billion of reported profit. The business underneath is performing, growing revenue 10.20% on a margin very few companies reach.
DON’T MISS: MongoDB (MDB) vs Snowflake (SNOW): Which is a Better Stock to Buy?
What the Balance Sheet Gave Up to Do It:
The acquisitions were not free, and the balance sheet shows the bill. AbbVie carries $70.88 billion of debt against $6.57 billion of cash, and book value per share is negative $3.36. The company has no shareholders’ equity left.
That is why no return on equity figure exists for AbbVie, and it is the real risk rather than the payout ratio. A company with equity can absorb a bad year by writing it off. A company without any equity absorbs it in the cash flow, which is the same cash flow paying the dividend.
So the structure only holds while the cash holds. There is no second line behind it. What makes that bearable is how little the market expects to go wrong. Short interest is 1.23% of the float and beta is 0.23, so these shares move roughly a quarter as much as the index.
A dividend funded by cash rather than earnings is a different kind of promise. Ten stocks positioned for high returns in 2026 are named here.
The Valuation Case:
AbbVie traded near $263 on October 5 and is worth $468.43 billion. Sustainability is about the drugs rather than the accounts. The 40.04% margin exists because the portfolio is protected, and every protection expires.
On price, the two multiples sit a long way apart, at 74.88 times trailing earnings against 16.39 times forward estimates. That collapse is the market pricing the amortization to run off and the reported earnings to catch up with the cash.
A PEG ratio of 0.54 sits well below one, which normally marks a stock priced under its own growth rate. The dividend yields 2.63% on a forward rate of $6.92 a share. This year’s best-performing dividend stocks are ranked here.
Conclusion:
The 190.40% payout ratio is measuring the wrong number. AbbVie generated $16.87 billion of free cash flow against $6.27 billion of reported earnings, and the gap is amortization of bought drugs rather than money going out of the door. Revenue grew 10.20% on a 40.04% operating margin. However, the real exposure is that $70.88 billion of debt sits on a balance sheet with no equity behind it, so a weak year lands directly on the cash flow. The number to watch is free cash flow, because the earnings line was never what funded this dividend.
Market Sentiment:
AbbVie Inc. was held by 88 hedge funds with a combined stake value of about $8.56 billion at the end of Q2 2026 in the Insider Monkey database. This is up from 87 hedge fund holders with a cumulative investment value of around $4.25 billion in the previous quarter.
READ NEXT: Here is Why Tripadvisor (TRIP) is a Bad Investment at Today’s Price and MongoDB (MDB) vs Snowflake (SNOW): Which is a Better Stock to Buy?
This article is originally published at Insider Monkey.
